Treatment Patterns and FLT3 Mutation Testing Among Patients with Acute Myeloid Leukemia in China: A Retrospective Observational Study

References

• Chen B-A, Huang Z-H, Zhang X-P, et al. An epidemiological investigation of leukemia incidence between 2003 and 2007 in Nanjing, China. J Hematol Oncol. 2010;3:21. doi:10.1186/1756-8722-3-21
   PubMed Web of Science ®Google Scholar
• Yi M, Li A, Zhou L, Chu Q, Song Y, Wu K. The global burden and attributable risk factor analysis of acute myeloid leukemia in 195 countries and territories from 1990 to 2017: estimates based on the global burden of disease study 2017. J Hematol Oncol. 2020;13(1):72. doi:10.1186/s13045-020-00908-z
   PubMed Web of Science ®Google Scholar
• Dong Y, Shi O, Zeng Q, et al. Leukemia incidence trends at the global, regional, and national level between 1990 and 2017. Exp Hematol Oncol. 2020;9:14. doi:10.1186/s40164-020-00170-6
   PubMed Web of Science ®Google Scholar
• Thol F, Ganser A. Treatment of relapsed acute myeloid leukemia. Curr Treat Options Oncol. 2020;21(8):66. doi:10.1007/s11864-020-00765-5
   PubMed Web of Science ®Google Scholar
• Newell LF, Cook RJ. Advances in acute myeloid leukemia. BMJ. 2021;375:n2026. doi:10.1136/bmj.n2026
   PubMedGoogle Scholar
• Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of relapsed/refractory acute myelogenous leukemia (2021). Zhonghua Xue Ye Xue Za Zhi. 2021;42(8):624–627. doi:10.3760/cma.j.issn.0253-2727.2021.08.002
   PubMedGoogle Scholar
• Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for the diagnosis and treatment of adult acute myeloid leukemia (not APL) (2021). Zhonghua Xue Ye Xue Za Zhi. 2021;42(8):617–623. doi:10.3760/cma.j.issn.0253-2727.2021.08.001
   PubMedGoogle Scholar
• Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345–1377. doi:10.1182/blood.2022016867
   PubMed Web of Science ®Google Scholar
• Thol F, Heuser M. Treatment for relapsed/refractory acute myeloid leukemia. HemaSphere. 2021;5(6):e572. doi:10.1097/HS9.0000000000000572
   PubMed Web of Science ®Google Scholar
• Ley TJ, Miller C, Ding L, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059–2074. doi:10.1056/NEJMoa1301689
   PubMed Web of Science ®Google Scholar
• Kennedy VE, Smith CC. FLT3 mutations in acute myeloid leukemia: key concepts and emerging controversies. Front Oncol. 2020;10:612880. doi:10.3389/fonc.2020.612880
   PubMed Web of Science ®Google Scholar
• Perl AE, Hosono N, Montesinos P, et al. Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. Blood Cancer J. 2022;12(5):84. doi:10.1038/s41408-022-00677-7
   PubMed Web of Science ®Google Scholar
• Nitika, Wei J, Hui A-M. Role of biomarkers in FLT3 AML. Cancers. 2022;14(5):1164. doi:10.3390/cancers14051164
   PubMed Web of Science ®Google Scholar
• Wang R-Q, Chen C-J, Jing Y, et al. Characteristics and prognostic significance of genetic mutations in acute myeloid leukemia based on a targeted next-generation sequencing technique. Cancer Med. 2020;9(22):8457–8467. doi:10.1002/cam4.3467
   PubMed Web of Science ®Google Scholar
• Gale RE, Green C, Allen C, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776–2784. doi:10.1182/blood-2007-08-109090
   PubMed Web of Science ®Google Scholar
• Bacher U, Haferlach C, Kern W, Haferlach T, Schnittger S. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients. Blood. 2008;111(5):2527–2537. doi:10.1182/blood-2007-05-091215
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447. doi:10.1182/blood-2016-08-733196
   PubMed Web of Science ®Google Scholar
• Astellas Pharma Inc. Astellas’ XOSPATA® (gilteritinib) receives conditional approval by china’s national medical products administration for relapsed or refractory acute myeloid leukemia with a FLT3 mutation. Available from: https://newsroom.astellas.us/2021-02-03-Astellas-XOSPATA-R-gilteritinib-Receives-Conditional-Approval-by-Chinas-National-Medical-Products-Administration-for-Relapsed-or-Refractory-Acute-Myeloid-Leukemia-with-A-FLT3-Mutation. Accessed September 22, 2022.
   Google Scholar
• Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML. N Engl J Med. 2019;381(18):1728–1740. doi:10.1056/NEJMoa1902688
   PubMed Web of Science ®Google Scholar
• Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377(5):454–464. doi:10.1056/NEJMoa1614359
   PubMed Web of Science ®Google Scholar
• Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299–312. doi:10.1038/s41375-018-0357-9
   PubMed Web of Science ®Google Scholar
• Griffin JD, Yang H, Song Y, Kinrich D, Shah MV, Bui CN. Treatment patterns and healthcare resource utilization in patients with FLT3-mutated and wild-type acute myeloid leukemia: a medical chart study. Eur J Haematol. 2019;102(4):341–350. doi:10.1111/ejh.13205
   PubMed Web of Science ®Google Scholar
• Cheson BD, Cassileth PA, Head DR, et al. Report of the national cancer institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8(5):813–819. doi:10.1200/JCO.1990.8.5.813
   PubMed Web of Science ®Google Scholar
• Koenig K, Mims A. Relapsed or primary refractory AML: moving past MEC and FLAG-ida. Curr Opin Hematol. 2020;27(2):108–114. doi:10.1097/MOH.0000000000000561
   PubMed Web of Science ®Google Scholar
• Xu J, Lv -T-T, Zhou X-F, Huang Y, Liu -D-D, Yuan G-L. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: a retrospective cohort study. Medicine. 2018;97(39):e12102. doi:10.1097/MD.0000000000012102
   PubMed Web of Science ®Google Scholar
• Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2017). Zhonghua Xue Ye Xue Za Zhi. 2017;38(3):177–182. doi:10.3760/cma.j.issn.0253-2727.2017.03.001
   PubMedGoogle Scholar
• Daver N, Venugopal S, Ravandi F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J. 2021;11(5):104. doi:10.1038/s41408-021-00495-3
   PubMed Web of Science ®Google Scholar
• Acute myeloid leukemia — cancer stat facts. Available from: https://seer.cancer.gov/statfacts/html/amyl.html. Accessed June 29, 2023.
   Google Scholar